Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 66Myelodysplastic Syndromes 38Leukemia, Myelomonocytic, Chronic 26Leukemia 14Myeloproliferative Disorders 10Recurrence 7Lymphoma 7Hematologic Neoplasms 7Neoplasms 6Primary Myelofibrosis 5Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm, Residual 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Glioblastoma 2Carcinoma, Renal Cell 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Cyclophosphamide 2sodium thiosulfate 1repotrectinib 1pralsetinib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1bintrafusp alfa protein, human 1Thrombopoietin 1Plicamycin 1Melphalan 1Mannitol 1ICE protocol 5 1Etoposide 1Drug Therapy 1Cytosine Deaminase 1Carboplatin 1Bevacizumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Germ Cell and Embryonal × Azacitidine × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡